Ruochuan Cheng

1.1k total citations
44 papers, 600 citations indexed

About

Ruochuan Cheng is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Oncology. According to data from OpenAlex, Ruochuan Cheng has authored 44 papers receiving a total of 600 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Endocrinology, Diabetes and Metabolism, 17 papers in Surgery and 11 papers in Oncology. Recurrent topics in Ruochuan Cheng's work include Thyroid Cancer Diagnosis and Treatment (34 papers), Thyroid and Parathyroid Surgery (15 papers) and Parathyroid Disorders and Treatments (5 papers). Ruochuan Cheng is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (34 papers), Thyroid and Parathyroid Surgery (15 papers) and Parathyroid Disorders and Treatments (5 papers). Ruochuan Cheng collaborates with scholars based in China, United States and Taiwan. Ruochuan Cheng's co-authors include Wen Liu, Hsing-Jien Kung, Li Xing, Frank Y.S. Chuang, Chun A. Changou, David K. Ann, Yun Yen, Richard J. Bold, Yun‐Ru Chen and Yanjun Su and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

Ruochuan Cheng

40 papers receiving 596 citations

Peers

Ruochuan Cheng
Yasuyo Nakajima Japan
Gengshu Wu Canada
Yasutaka Takeda Japan
Cecilia Vitali United States
Hidemitsu Sakagami Japan
Stefan Tschopp Switzerland
Mako Yasuda‒Yamahara Japan
Yumi Jimbu Japan
F. Ravandi Kashani Germany
Yumiko Nakagawa-Toyama Japan
Yasuyo Nakajima Japan
Ruochuan Cheng
Citations per year, relative to Ruochuan Cheng Ruochuan Cheng (= 1×) peers Yasuyo Nakajima

Countries citing papers authored by Ruochuan Cheng

Since Specialization
Citations

This map shows the geographic impact of Ruochuan Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruochuan Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruochuan Cheng more than expected).

Fields of papers citing papers by Ruochuan Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruochuan Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruochuan Cheng. The network helps show where Ruochuan Cheng may publish in the future.

Co-authorship network of co-authors of Ruochuan Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Ruochuan Cheng. A scholar is included among the top collaborators of Ruochuan Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruochuan Cheng. Ruochuan Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Pei, Zhizhong Dong, Yanjun Su, et al.. (2025). Single-cell transcriptomics analysis reveals that the tumor-infiltrating B cells determine the indolent fate of papillary thyroid carcinoma. Journal of Experimental & Clinical Cancer Research. 44(1). 91–91. 1 indexed citations
2.
Wang, Pei, Zhizhong Dong, Yanjun Su, et al.. (2024). Trends of the prevalence rate of central lymph node metastasis and multifocality in patients with low-risk papillary thyroid carcinoma after delayed thyroid surgery. Frontiers in Endocrinology. 15. 1349272–1349272. 3 indexed citations
3.
Liu, Bin, et al.. (2024). Treatment and management of medullary thyroid microcarcinoma: a 10-year retrospective study from a single center. Endocrine. 86(3). 1081–1089. 2 indexed citations
4.
Ji, Qing, Ruochuan Cheng, Wei Tian, et al.. (2024). [Controversy and comments on some recommendations of the Expert Consensus on Thermal Ablation Therapy of Papillary Thyroid Cancer (2024 Edition)].. PubMed. 59(10). 1088–1093. 1 indexed citations
5.
Chi, Yihebali, Xiangqian Zheng, Ying Cheng, et al.. (2023). Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial. Clinical Cancer Research. 29(20). 4047–4056. 15 indexed citations
6.
7.
Cheng, Ruochuan, et al.. (2023). TPO as an indicator of lymph node metastasis and recurrence in papillary thyroid carcinoma. Scientific Reports. 13(1). 10848–10848. 10 indexed citations
8.
Liu, Wen, Zhizhong Dong, Yanjun Su, et al.. (2022). A Mathematical Model to Assess the Effect of Residual Positive Lymph Nodes on the Survival of Patients With Papillary Thyroid Microcarcinoma. Frontiers in Oncology. 12. 855830–855830. 2 indexed citations
9.
10.
Dong, Zhizhong, Wen Liu, Feng Su, & Ruochuan Cheng. (2022). Association of Body Mass Index With Clinicopathological Features of Papillary Thyroid Carcinoma: A Retrospective Study. Endocrine Practice. 29(2). 83–88. 1 indexed citations
11.
Li, Dapeng, Yihebali Chi, Minghua Ge, et al.. (2021). Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial. Clinical Cancer Research. 27(13). 3567–3575. 78 indexed citations
12.
Mao, Ying, et al.. (2021). The role of P62 in the development of human thyroid cancer and its possible mechanism. Cancer Genetics. 256-257. 5–16. 3 indexed citations
13.
Liu, Wen, et al.. (2021). The active surveillance management approach for patients with low risk papillary thyroid microcarcinomas: is China ready?. Cancer Biology and Medicine. 19(5). 619–634. 9 indexed citations
14.
Ming, Jie, Jingqiang Zhu, Hao Zhang, et al.. (2021). A multicenter, prospective study to observe the initial management of patients with differentiated thyroid cancer in China (DTCC study). BMC Endocrine Disorders. 21(1). 208–208. 10 indexed citations
15.
Chi, Yihebali, Ming Gao, Feng Shi, et al.. (2020). LBA88 Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial. Annals of Oncology. 31. S1215–S1215. 6 indexed citations
16.
Gao, Ming, Ying Cheng, Zhixing Guo, et al.. (2020). 265O Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial. Annals of Oncology. 31. S1347–S1347. 7 indexed citations
17.
Liu, Wen, et al.. (2020). Continuing controversy regarding individualized surgical decision-making for patients with 1–4 cm low-risk differentiated thyroid carcinoma: A systematic review. European Journal of Surgical Oncology. 46(12). 2174–2184. 14 indexed citations
18.
Zhao, Bing, et al.. (2015). Expression of MUC1 and CD176 (Thomsen-Friedenreich antigen) in Papillary Thyroid Carcinomas. Endocrine Pathology. 26(1). 21–26. 5 indexed citations
19.
Rajan, Neil, Anna Kaltenboeck, Jasmina Ivanova, et al.. (2014). HEALTH CARE RESOURCE USE AMONG ADVANCED GASTRIC CANCER PATIENTS IN TAIWAN AND SOUTH KOREA. Value in Health. 17(7). A734–A734. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yasuyo Nakajima Breakdown of academic impact, for papers by Gengshu Wu Breakdown of academic impact, for papers by Yasutaka Takeda Breakdown of academic impact, for papers by Cecilia Vitali Breakdown of academic impact, for papers by Hidemitsu Sakagami Breakdown of academic impact, for papers by Stefan Tschopp Breakdown of academic impact, for papers by Mako Yasuda‒Yamahara Breakdown of academic impact, for papers by Yumi Jimbu Breakdown of academic impact, for papers by F. Ravandi Kashani Breakdown of academic impact, for papers by Yumiko Nakagawa-Toyama
Rankless by CCL
2026